Print PDF

Sheppard Mullin Advises Unicycive Therapeutics in $50 Million Private Placement


The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $50 million private placement.

The financing is led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing healthcare institutional investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital and Walleye Capital.

Sheppard Mullin previously advised Unicycive in its $130 million private placement in March 2023.

The deal was led by partner and co-leader of the firm’s Life Sciences team Jeff Fessler and special counsel Greg Carney.

Click here to read the press release.

Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.